Literature DB >> 19108570

Circulating autoantibodies to troponin I in Emery-Dreifuss muscular dystrophy.

I Niebroj-Dobosz1, M Marchel, A Madej, B Sokolowska, I Hausmanowa-Petrusewicz.   

Abstract

The pathogenesis of dilated cardiomyopathy in Emery- Dreifuss muscular dystrophy (EDMD) is still unknown. Autoimmune mechanisms have recently been taken into account. The aim of this investigation was to determine whether the level of circulating antibodies to heart proteins which were previously detected, correlates with disease progression. Troponin I was chosen as the target. Ten patients with EDMD and 10 age-matched normal controls were tested. An enzyme linked immunoassay (ELISA) technique was used to determine the possible relation between the level of anti-troponin I antibodies at diagnosis and at followup. Autoantibodies against troponin I were detected in all EDMD patients. At diagnosis the level was higher in the X-linked EDMD form (X-EDMD), as compared to the autosomal dominant form (AD-EDMD). At follow-up the elevated level of the autoantibodies persisted in all the EDMD cases. However, in the AD-EDMD form, the level was found to be significantly rising with disease progression, in the X-EDMD form, on the other hand, it was declining. No clear-cut relationship between the level of the circulating antibodies and cardiac symptomatology was present. Detection of anti-troponin I antibodies may provide a non-invasive marker of early stages of dilated cardiomyopathy in EDMD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19108570      PMCID: PMC2859608     

Source DB:  PubMed          Journal:  Acta Myol        ISSN: 1128-2460


  28 in total

1.  Antibodies to the ADP/ATP carrier, an autoantigen in myocarditis and dilated cardiomyopathy, penetrate into myocardial cells and disturb energy metabolism in vivo.

Authors:  K Schulze; B F Becker; H P Schultheiss
Journal:  Circ Res       Date:  1989-02       Impact factor: 17.367

2.  Natural history of dilated cardiomyopathy due to lamin A/C gene mutations.

Authors:  Matthew R G Taylor; Pamela R Fain; Gianfranco Sinagra; Misi L Robinson; Alastair D Robertson; Elisa Carniel; Andrea Di Lenarda; Teresa J Bohlmeyer; Debra A Ferguson; Gary L Brodsky; Mark M Boucek; Jean Lascor; Andrew C Moss; Wai Lun P Li; Gary L Stetler; Francesco Muntoni; Michael R Bristow; Luisa Mestroni
Journal:  J Am Coll Cardiol       Date:  2003-03-05       Impact factor: 24.094

3.  Autoimmune markers are undetectable in end stage idiopathic dilated cardiomyopathy.

Authors:  N de Leeuw; W J Melchers; D J Ruiter; A L Caforio; A H Balk; N de Jonge; J M Galama
Journal:  J Clin Pathol       Date:  1999-10       Impact factor: 3.411

4.  Antibodies to ADP-ATP carrier--an autoantigen in myocarditis and dilated cardiomyopathy--impair cardiac function.

Authors:  K Schulze; B F Becker; R Schauer; H P Schultheiss
Journal:  Circulation       Date:  1990-03       Impact factor: 29.690

5.  Temporal activation of c-Jun N-terminal kinase in adult transgenic heart via cre-loxP-mediated DNA recombination.

Authors:  Brian G Petrich; Jeffery D Molkentin; Yibin Wang
Journal:  FASEB J       Date:  2003-02-19       Impact factor: 5.191

6.  Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice.

Authors:  Taku Okazaki; Yoshimasa Tanaka; Ryosuke Nishio; Tamotsu Mitsuiye; Akira Mizoguchi; Jian Wang; Masayoshi Ishida; Hiroshi Hiai; Akira Matsumori; Nagahiro Minato; Tasuku Honjo
Journal:  Nat Med       Date:  2003-11-02       Impact factor: 53.440

7.  Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice.

Authors:  Vesna Nikolova; Christiana Leimena; Aisling C McMahon; Ju Chiat Tan; Suchitra Chandar; Dilesh Jogia; Scott H Kesteven; Jan Michalicek; Robyn Otway; Fons Verheyen; Stephen Rainer; Colin L Stewart; David Martin; Michael P Feneley; Diane Fatkin
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

8.  Humoral immunity in cardiomyopathy.

Authors:  P J Lowry; R A Thompson; W A Littler
Journal:  Br Heart J       Date:  1983-10

9.  Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement.

Authors:  G L Brodsky; F Muntoni; S Miocic; G Sinagra; C Sewry; L Mestroni
Journal:  Circulation       Date:  2000-02-08       Impact factor: 29.690

10.  Antibody-mediated enhancement of calcium permeability in cardiac myocytes.

Authors:  H P Schultheiss; U Kühl; I Janda; B Melzner; G Ulrich; M Morad
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

View more
  3 in total

Review 1.  Anti-cardiac troponin antibodies in clinical human disease: a systematic review.

Authors:  Eduardo M Vilela; Rita Bettencourt-Silva; J Torres da Costa; Ana Raquel Barbosa; Marisa P Silva; Madalena Teixeira; João Primo; Vasco Gama Ribeiro; José Pedro L Nunes
Journal:  Ann Transl Med       Date:  2017-08

2.  The effect of the lamin A and its mutants on nuclear structure, cell proliferation, protein stability, and mobility in embryonic cells.

Authors:  Katarzyna Piekarowicz; Magdalena Machowska; Ewelina Dratkiewicz; Daria Lorek; Agnieszka Madej-Pilarczyk; Ryszard Rzepecki
Journal:  Chromosoma       Date:  2016-08-17       Impact factor: 4.316

3.  Autosomal dominant Emery-Dreifuss muscular dystrophy caused by a mutation in the lamin A/C gene identified by exome sequencing: a case report.

Authors:  Kristy Iskandar; Farida Niken Astari; Rizki Amalia Gumilang; Nissya Ilma; Ni Putu Shartyanie; Guritno Adistyawan; Grace Tan; Poh San Lai
Journal:  BMC Pediatr       Date:  2022-10-17       Impact factor: 2.567

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.